PRMT5 and neuroblastoma: A significant finding from the current study, which arose through measuring gene expression in clinically annotated biobanks of human NB biopsies, has established for the first time that MYCN, PRMT5 and E2F1 are frequently co‐expressed at high levels in poor prognosis high‐risk disease.